DailyIQ
|
Sector:HealthcareAll sectors
Last updated 2 minutes ago

CRSP·CRISPR Therapeutics AG

$.
+. (+.%)
After Hours
High
$54.53
Open
$51.74
Market Cap
4.98B
52W High
$78.48
Low
$51.00
P. Close
$53.54
P/E
-
52W Low
$35.38
Fwd P/E
-13.36
Mean Target
$82.24
Technical Score (1D)
36
SELL
News Sentiment
60
BULLISH
CRISPR Therapeutics' gene-editing therapy, Casgevy, has received approval for sickle cell disease and beta-thalassemia, marking a significant clinical advancement. This development positions the company within the growing gene-editing biotechnology sector. Investors are closely watching CRISPR Therapeutics as it is being evaluated against competitors like Beam Therapeutics, with upcoming catalysts expected to influence performance.
Earnings Summary
CRISPR Therapeutics AG is a biotechnology company focused on developing novel gene-editing therapies using its proprietary CRISPR/Cas9 platform. The company aims to create potentially curative treatments for serious diseases, with a primary focus on hemoglobinopathies and a pipeline targeting oncology, autoimmune diseases, and other conditions. CRISPR Therapeutics operates within the dynamic and highly innovative biotechnology sector, characterized by significant research and development investment and regulatory scrutiny. In its most recent reported quarters, CRSP demonstrated a trend of improving actual earnings per share (EPS) compared to analyst estimates, with EPS moving from a loss of -1.58 in Q1 2025 to -1.17 in Q3 2025, exceeding expectations in both periods. Revenue, while still nascent, saw a significant increase from $0.87 million in Q2 2025 to $0.89 million in Q3 2025, indicating early commercial traction. Historically, the company has shown a pattern of consistent revenue growth, though EPS has largely remained in negative territory as is common for development-stage biotechs. For instance, comparing Q4 2024's actual EPS of -0.44 to Q1 2025's -1.58 shows a widening loss, but Q2 2025 and Q3 2025 saw sequential improvements in EPS relative to estimates. Recent news highlights CRISPR Therapeutics entering a new phase focused on pipeline development following the launch of CASGEVY, with expectations for data from six pipeline assets within 12-18 months. The CEO has indicated 2026 as a critical year for significant readouts from early-stage programs. Investors will be watching for upcoming pipeline data readouts and clinical trial updates, as well as the continued commercial momentum and reimbursement timelines for CASGEVY, to gauge future growth drivers and the company's ability to balance pipeline advancement with commercialization efforts.

EPS

EstBeatMiss
$-1.75$-1.38$-1.01$-0.64$-0.27Q4'24Q1'25Q2'25Q3'25Q4'25
QtrEstActual+/−
Q4'25$-1.18 - -
Q3'25$-1.29$-1.17+9.2%
Q2'25$-1.40$-1.29+7.8%
Q1'25$-1.28$-1.58-23.8%
Q4'24$-1.19$-0.44+62.9%

Revenue

EstBeatMiss
$-4M$7M$18M$30M$41MQ4'24Q1'25Q2'25Q3'25Q4'25
QtrEstActual+/−
Q4'25$6M - -
Q3'25 - $889,000 -
Q2'25 - $892,000 -
Q1'25 - $865,000 -
Q4'24 - $36M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

CRSP Stock Snapshot

CRSP is currently trading at $53.65, giving CRISPR Therapeutics AG a market cap of 4.98B. Today's range spans $51.00–$54.53, with shares opening at $51.74 and moving up $0.11 (0.2%) from the prior close. DailyIQ's technical score sits at 36/100 (HOLD) with a news sentiment reading of 60/100.

Over the past year CRSP has traded between $35.38 and $78.48 - the current price is +51.6% off the 52-week low and -31.6% from the high. 36 analysts cover the stock with a Buy consensus and a mean 12-month target of $82.24 (range $33.00–$291.00), implying upside of +53.3%.

The technical setup for CRISPR Therapeutics AG (CRSP) (small-cap, 4.98B market cap, Healthcare) is in negative territory: 36/100, HOLD, with bullish sentiment at 60/100. Price: $53.65 (in the middle of its 52-week range). The 52-week range of $35.38–$78.48 defines the boundaries, and the HOLD signal at this size often means that the marginal buyer has stepped back entirely - leaving price action vulnerable to any incremental selling.

The absence of strong institutional sponsorship makes CRSP's HOLD signal (36/100) more consequential than the same signal in a larger name — at 4.98B in Healthcare market cap, there are fewer natural buyers to absorb selling pressure, which means the $35.38–$78.48 range's lower bound becomes a sharper test of the thesis. Sentiment at 60/100 (bullish) and price at $53.65 (in the middle of its 52-week range) don't yet suggest stabilization is imminent.